Pembrolizumab (anti-PD-1)

Catalog No.A2005        Batch: A200507

Print

Technical Data

CAS No. 1374853-91-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 22.61mg/ml
Endotoxin Level ＜1EU/mg

Biological Activity

Description Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Targets
PD-1 [1]
(Cell-free assay)
In vitro

The level of LDH and apoptosis are significantly higher in those treated with dexamethasone plus PD1 inhibitor pembrolizumab than other groups.[1]
In vivo

Pembrolizumab and dexamethasone synergistically suppress tumor growth of pancreatic cancer in vivo.[1]

Protocol (Only for Reference)

Cell Assay:

  • Cancer cells were incubated with dexamethasone for 48 h followed by co-cultured with PBMCs with effector/target ratio of 10:1 and the addition of PD1 inhibitor (pembrolizumab; 5 μg/mL) for another 48 h. LDH level was detected.
Animal Study:

  • Animal Models: Immune reconstituted NOD/SCID mice model
    Dosages: 5 mg/kg
    Administration: i.v.
    Reference: [1]
     

Selleck's Pembrolizumab (anti-PD-1) has been cited by 49 publications

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [ Nat Med, 2024, 10.1038/s41591-024-02824-y] PubMed: 38374347
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation [ Cell Mol Immunol, 2024, 21(1):60-79] PubMed: 38062129
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors [ Life Sci Alliance, 2024, 7(3)e202302368] PubMed: 38176728
[ BMC Cancer, 2024, ] PubMed: 38409035
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] PubMed: none
A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal [ Signal Transduct Target Ther, 2023, 8(1):312] PubMed: 37607946
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma [ J Exp Clin Cancer Res, 2023, 42(1):251] PubMed: 37759291
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer [ Int J Cancer, 2023, 153(1):224-237] PubMed: 36799619
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer [ Int J Cancer, 2023, 153(1):224-237] PubMed: 36799619
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis [ Respir Res, 2023, 24(1):279] PubMed: 37964265

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.